NYSE:EWEdwards Lifesciences Competitors & Alternatives

Edwards Lifesciences (NYSE:EW) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.

Insider and Institutional Ownership

80.7% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 73.6% of Abbott Laboratories shares are held by institutional investors. 1.5% of Edwards Lifesciences shares are held by company insiders. Comparatively, 1.7% of Abbott Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Edwards Lifesciences has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.

Profitability

This table compares Edwards Lifesciences and Abbott Laboratories' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Edwards Lifesciences and Abbott Laboratories' revenue, earnings per share and valuation.

Abbott Laboratories has higher revenue and earnings than Edwards Lifesciences. Abbott Laboratories is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Edwards Lifesciences and Abbott Laboratories, as provided by MarketBeat.com.

Edwards Lifesciences presently has a consensus price target of $82.7727, indicating a potential upside of 19.63%. Abbott Laboratories has a consensus price target of $100.2667, indicating a potential upside of 8.71%. Given Edwards Lifesciences' stronger consensus rating and higher probable upside, analysts clearly believe Edwards Lifesciences is more favorable than Abbott Laboratories.

Summary

Edwards Lifesciences beats Abbott Laboratories on 8 of the 14 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends.

Risk & Volatility

Edwards Lifesciences has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.

Earnings and Valuation

This table compares Edwards Lifesciences and Medtronic's top-line revenue, earnings per share and valuation.

Medtronic has higher revenue and earnings than Edwards Lifesciences. Medtronic is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Edwards Lifesciences and Medtronic, as reported by MarketBeat.

Edwards Lifesciences presently has a consensus price target of $82.7727, indicating a potential upside of 19.63%. Medtronic has a consensus price target of $114.5333, indicating a potential upside of 22.94%. Given Medtronic's stronger consensus rating and higher probable upside, analysts clearly believe Medtronic is more favorable than Edwards Lifesciences.

Insider & Institutional Ownership

80.7% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 81.1% of Medtronic shares are held by institutional investors. 1.5% of Edwards Lifesciences shares are held by company insiders. Comparatively, 0.3% of Medtronic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Edwards Lifesciences and Medtronic's net margins, return on equity and return on assets.

Summary

Medtronic beats Edwards Lifesciences on 8 of the 15 factors compared between the two stocks.

Stryker (NYSE:SYK) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk and valuation.

Risk & Volatility

Stryker has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Valuation & Earnings

This table compares Stryker and Edwards Lifesciences' revenue, earnings per share (EPS) and valuation.

Stryker has higher revenue and earnings than Edwards Lifesciences. Stryker is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Stryker and Edwards Lifesciences' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Stryker and Edwards Lifesciences, as provided by MarketBeat.

Stryker currently has a consensus target price of $215.20, suggesting a potential upside of 16.99%. Edwards Lifesciences has a consensus target price of $82.7727, suggesting a potential upside of 19.63%. Given Edwards Lifesciences' higher possible upside, analysts clearly believe Edwards Lifesciences is more favorable than Stryker.

Insider & Institutional Ownership

71.3% of Stryker shares are held by institutional investors. Comparatively, 80.7% of Edwards Lifesciences shares are held by institutional investors. 6.8% of Stryker shares are held by company insiders. Comparatively, 1.5% of Edwards Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Edwards Lifesciences beats Stryker on 8 of the 15 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Edwards Lifesciences and Intuitive Surgical, as provided by MarketBeat.

Edwards Lifesciences currently has a consensus target price of $82.7727, suggesting a potential upside of 19.63%. Intuitive Surgical has a consensus target price of $571.1176, suggesting a potential downside of 1.61%. Given Edwards Lifesciences' stronger consensus rating and higher probable upside, analysts plainly believe Edwards Lifesciences is more favorable than Intuitive Surgical.

Earnings and Valuation

This table compares Edwards Lifesciences and Intuitive Surgical's gross revenue, earnings per share and valuation.

Intuitive Surgical has higher revenue and earnings than Edwards Lifesciences. Edwards Lifesciences is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Edwards Lifesciences has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.

Institutional & Insider Ownership

80.7% of Edwards Lifesciences shares are owned by institutional investors. Comparatively, 87.3% of Intuitive Surgical shares are owned by institutional investors. 1.5% of Edwards Lifesciences shares are owned by insiders. Comparatively, 1.6% of Intuitive Surgical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Edwards Lifesciences and Intuitive Surgical's net margins, return on equity and return on assets.

Summary

Intuitive Surgical beats Edwards Lifesciences on 9 of the 14 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and Becton Dickinson and (NYSE:BDX) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Edwards Lifesciences and Becton Dickinson and, as provided by MarketBeat.

Edwards Lifesciences currently has a consensus target price of $82.7727, suggesting a potential upside of 19.63%. Becton Dickinson and has a consensus target price of $273.80, suggesting a potential upside of 11.74%. Given Edwards Lifesciences' stronger consensus rating and higher probable upside, analysts plainly believe Edwards Lifesciences is more favorable than Becton Dickinson and.

Earnings and Valuation

This table compares Edwards Lifesciences and Becton Dickinson and's gross revenue, earnings per share and valuation.

Becton Dickinson and has higher revenue and earnings than Edwards Lifesciences. Becton Dickinson and is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Edwards Lifesciences has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Comparatively, Becton Dickinson and has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.

Institutional & Insider Ownership

80.7% of Edwards Lifesciences shares are owned by institutional investors. Comparatively, 85.8% of Becton Dickinson and shares are owned by institutional investors. 1.5% of Edwards Lifesciences shares are owned by insiders. Comparatively, 0.1% of Becton Dickinson and shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Edwards Lifesciences and Becton Dickinson and's net margins, return on equity and return on assets.

Summary

Edwards Lifesciences beats Becton Dickinson and on 8 of the 14 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Profitability

This table compares Edwards Lifesciences and Boston Scientific's net margins, return on equity and return on assets.

Institutional and Insider Ownership

80.7% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 90.1% of Boston Scientific shares are held by institutional investors. 1.5% of Edwards Lifesciences shares are held by insiders. Comparatively, 0.7% of Boston Scientific shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Edwards Lifesciences has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.

Valuation and Earnings

This table compares Edwards Lifesciences and Boston Scientific's gross revenue, earnings per share and valuation.

Boston Scientific has higher revenue and earnings than Edwards Lifesciences. Boston Scientific is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Edwards Lifesciences and Boston Scientific, as provided by MarketBeat.

Edwards Lifesciences currently has a consensus target price of $82.7727, suggesting a potential upside of 19.63%. Boston Scientific has a consensus target price of $44.6522, suggesting a potential upside of 26.21%. Given Boston Scientific's stronger consensus rating and higher probable upside, analysts clearly believe Boston Scientific is more favorable than Edwards Lifesciences.

Summary

Boston Scientific beats Edwards Lifesciences on 9 of the 15 factors compared between the two stocks.